Mike Lau

672 total citations
25 papers, 351 citations indexed

About

Mike Lau is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mike Lau has authored 25 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mike Lau's work include Melanoma and MAPK Pathways (13 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Mike Lau is often cited by papers focused on Melanoma and MAPK Pathways (13 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Mike Lau collaborates with scholars based in United Kingdom, France and United States. Mike Lau's co-authors include Philippe Legenne, Natalie Compton, Janet Shipley, Richard A. Brown, Yong‐Jie Lu, Éva Remenár, Kevin J. Harrington, Michael Fry, Hisham Mehanna and Jérôme Fayette and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Mike Lau

24 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mike Lau United Kingdom	9	197	173	138	66	31	25	351
Francesca Consoli Italy	9	209 1.1×	92 0.5×	72 0.5×	55 0.8×	38 1.2×	37	367
Christian P. Turtschi Switzerland	4	200 1.0×	336 1.9×	166 1.2×	9 0.1×	47 1.5×	4	486
Luke Walker United States	10	272 1.4×	253 1.5×	255 1.8×	56 0.8×	30 1.0×	39	489
Yunjian Huang China	9	217 1.1×	65 0.4×	182 1.3×	68 1.0×	69 2.2×	30	345
Zhiqiang Mo China	10	153 0.8×	246 1.4×	68 0.5×	11 0.2×	61 2.0×	23	466
P. Francis Canada	6	240 1.2×	201 1.2×	154 1.1×	144 2.2×	62 2.0×	8	416
Xinqiong Huang China	11	111 0.6×	171 1.0×	45 0.3×	62 0.9×	40 1.3×	18	347
Kate Young United Kingdom	11	240 1.2×	92 0.5×	115 0.8×	5 0.1×	33 1.1×	30	365
Sonia Garofalo Italy	6	189 1.0×	145 0.8×	126 0.9×	5 0.1×	20 0.6×	7	364
Lina Inagaki Japan	7	165 0.8×	54 0.3×	87 0.6×	11 0.2×	27 0.9×	14	327

Countries citing papers authored by Mike Lau

Since Specialization

Citations

This map shows the geographic impact of Mike Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Lau more than expected).

Fields of papers citing papers by Mike Lau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Lau. The network helps show where Mike Lau may publish in the future.

Co-authorship network of co-authors of Mike Lau

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Lau. A scholar is included among the top collaborators of Mike Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Lau. Mike Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tay, Rong En, Nicholas Ang, Diana López, et al.. (2025). Serotonin receptor 5-HT_2A as a potential target for HCC immunotherapy. Journal for ImmunoTherapy of Cancer. 13(6). e011088–e011088. 3 indexed citations

Márquez‐Rodas, Iván, Luigi Formisano, Sophie Papa, et al.. (2022). Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR Cancer. 8(2). e35930–e35930. 5 indexed citations

Lijnsvelt, J., Alfredo Addeo, Maria Giuseppa Vitale, et al.. (2022). 840P Electronic patient-reported outcomes (ePROs) of adults with BRAF V600–mutant stage III-IV melanoma treated with dabrafenib + trametinib (D + T) collected using the Kaiku Health digital patient (pt) monitoring platform. Annals of Oncology. 33. S933–S934. 2 indexed citations

Nathan, Paul, Jean‐Jacques Grob, Reinhard Dummer, et al.. (2022). 819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial. Annals of Oncology. 33. S921–S922. 3 indexed citations

Atkinson, Victoria, Caroline Robert, Jean‐Jacques Grob, et al.. (2022). Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European Journal of Cancer. 163. 79–87. 15 indexed citations

Schadendorf, Dirk, Axel Hauschild, Mario Mandalà, et al.. (2022). Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAF^V600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.. Journal of Clinical Oncology. 40(16_suppl). 9563–9563. 2 indexed citations

White, Michael G., Christopher P. Vellano, Miles C. Andrews, et al.. (2022). Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.. Journal of Clinical Oncology. 40(16_suppl). 9523–9523. 1 indexed citations

Schadendorf, Dirk, Caroline Robert, Reinhard Dummer, et al.. (2021). Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer. 153. 234–241. 16 indexed citations

Atkinson, Victoria, Shahneen Sandhu, Geke A.P. Hospers, et al.. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research. 30(3). 261–267. 25 indexed citations

10.

Kirkwood, John M., Reinhard Dummer, Axel Hauschild, et al.. (2020). 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma. Annals of Oncology. 31. S743–S744.

11.

Saleem, Azeem, Graham E. Searle, Laura Kenny, et al.. (2015). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Research. 5(1). 30–30. 58 indexed citations

12.

Ramlau, Rodryg, Michael Thomas, Silvia Novello, et al.. (2015). Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. Clinical Lung Cancer. 16(5). 348–357. 16 indexed citations

13.

Atkinson, Victoria, Johannes V. van Thienen, Grant A. McArthur, et al.. (2015). 3337 Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study. European Journal of Cancer. 51. S677–S678. 2 indexed citations

14.

Crown, John, Megan Kennedy, Patricia Tresca, et al.. (2013). Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of Oncology. 24(8). 2005–2011. 12 indexed citations

15.

Saleem, Azeem, Graham E. Searle, Laura Kenny, et al.. (2013). Brain and tumor penetration of carbon-11–labeled lapatinib ([¹¹C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).. Journal of Clinical Oncology. 31(15_suppl). 635–635. 2 indexed citations

16.

Harrington, Kevin J., Martin Robinson, Éva Remenár, et al.. (2012). Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. European Journal of Cancer. 49(7). 1609–1618. 89 indexed citations

17.

El‐Hariry, Iman, Thomas Powles, Mike Lau, et al.. (2010). Amplification of epidermal growth factor receptor gene in renal cell carcinoma. European Journal of Cancer. 46(5). 859–862. 8 indexed citations

18.

Escudier, B., David Cella, C. Sternberg, et al.. (2010). A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 28(15_suppl). TPS237–TPS237. 4 indexed citations

19.

Harrington, Kevin J., Max Robinson, Éva Remenár, et al.. (2010). Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 28(15_suppl). 5505–5505. 21 indexed citations

20.

Lu, Yong‐Jie, et al.. (1998). cDNA Cloning of a Third Human C2-Domain-Containing Class II Phosphoinositide 3-Kinase, PI3K-C2γ, and Chromosomal Assignment of This Gene (PIK3C2G) to 12p12. Genomics. 54(3). 569–574. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact